Literature DB >> 7678229

B7/BB1, the ligand for CD28, is expressed on repeatedly activated human T cells in vitro.

D M Sansom1, N D Hall.   

Abstract

The activation of T cells is now thought to require at least two distinct signals. One signal is delivered through the interaction of the antigen-specific T cell receptor with major histocompatibility complex (MHC) molecules and peptide, while the other is received from interactions with less precisely defined accessory or costimulatory molecules. In the absence of this second costimulatory signal, some T cells subsequently become unresponsive to antigenic stimulation. One of the major candidates for providing such a second signal to T cells is the molecule B7 interacting with the T cell glycoprotein CD28. In the present study we have investigated whether B7 is expressed on human T cell lines and clones, since these cells have the capacity to present antigen to each other by expressing MHC class II molecules. Our results demonstrate that B7 can be detected on T cell clones and on repeatedly activated but not freshly isolated peripheral blood T cells. The expression of B7 is dependent on the state of activation of the cells, being maximally expressed shortly after restimulation and becoming undetectable as the cells quiesce. Together, these results suggest that B7 expression may be of importance to T cells, perhaps in the avoidance of anergy.

Entities:  

Mesh:

Substances:

Year:  1993        PMID: 7678229     DOI: 10.1002/eji.1830230148

Source DB:  PubMed          Journal:  Eur J Immunol        ISSN: 0014-2980            Impact factor:   5.532


  22 in total

Review 1.  The contributions of T-cell anergy to peripheral T-cell tolerance.

Authors:  R Lechler; J G Chai; F Marelli-Berg; G Lombardi
Journal:  Immunology       Date:  2001-07       Impact factor: 7.397

Review 2.  CD28, CTLA-4 and their ligands: who does what and to whom?

Authors:  D M Sansom
Journal:  Immunology       Date:  2000-10       Impact factor: 7.397

3.  Treatment with anti-CD86 costimulatory molecule prevents the autoimmune lesions in murine Sjögren's syndrome (SS) through up-regulated Th2 response.

Authors:  K Saegusa; N Ishimaru; K Yanagi; N Haneji; M Nishino; M Azuma; I Saito; Y Hayashi
Journal:  Clin Exp Immunol       Date:  2000-02       Impact factor: 4.330

4.  Novel insights in the regulation of the immune system: a report on the FASEB summer research conference on autoimmunity (June 14-19, 2003, Saxton's River, Vermont, USA).

Authors:  Matthew A Gronski
Journal:  Rev Diabet Stud       Date:  2004-05-10

5.  Down-regulation of Th2 responses by Brucella abortus, a strong Th1 stimulus, correlates with alterations in the B7.2-CD28 pathway.

Authors:  I Agranovich; D E Scott; D Terle; K Lee; B Golding
Journal:  Infect Immun       Date:  1999-09       Impact factor: 3.441

6.  B7/CD28 but not LFA-3/CD2 interactions can provide 'third-party' co-stimulation for human T-cell activation.

Authors:  D M Sansom; A Wilson; M Boshell; J Lewis; N D Hall
Journal:  Immunology       Date:  1993-10       Impact factor: 7.397

7.  Effects of antigen presentation on superantigen-induced apoptosis mediated by Fas/Fas ligand interactions in human T cells.

Authors:  M Boshell; J McLeod; L Walker; N Hall; Y Patel; D Sansom
Journal:  Immunology       Date:  1996-04       Impact factor: 7.397

8.  Induction of abortive and productive proliferation in resting human T lymphocytes via CD3 and CD28.

Authors:  Y Müller; H Wolf; E Wierenga; G Jung
Journal:  Immunology       Date:  1999-06       Impact factor: 7.397

9.  Expression of CD80 and CD86 on peripheral blood T lymphocytes in patients with systemic lupus erythematosus.

Authors:  K Abe; Y Takasaki; C Ushiyama; J Asakawa; T Fukazawa; M Seki; M Hirashima; M Ogaki; H Hashimoto
Journal:  J Clin Immunol       Date:  1999-01       Impact factor: 8.317

10.  Costimulation of T-cell activation and virus production by B7 antigen on activated CD4+ T cells from human immunodeficiency virus type 1-infected donors.

Authors:  O K Haffar; M D Smithgall; J Bradshaw; B Brady; N K Damle; P S Linsley
Journal:  Proc Natl Acad Sci U S A       Date:  1993-12-01       Impact factor: 11.205

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.